TW209215B - - Google Patents

Download PDF

Info

Publication number
TW209215B
TW209215B TW081108267A TW81108267A TW209215B TW 209215 B TW209215 B TW 209215B TW 081108267 A TW081108267 A TW 081108267A TW 81108267 A TW81108267 A TW 81108267A TW 209215 B TW209215 B TW 209215B
Authority
TW
Taiwan
Prior art keywords
compound
group
formula
ministry
solution
Prior art date
Application number
TW081108267A
Other languages
English (en)
Chinese (zh)
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Application granted granted Critical
Publication of TW209215B publication Critical patent/TW209215B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/101,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/141,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/221,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one naphthalene or hydrogenated naphthalene ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Steroid Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
TW081108267A 1991-10-17 1992-10-17 TW209215B (member.php)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP29811991 1991-10-17

Publications (1)

Publication Number Publication Date
TW209215B true TW209215B (member.php) 1993-07-11

Family

ID=17855421

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081108267A TW209215B (member.php) 1991-10-17 1992-10-17

Country Status (12)

Country Link
US (4) US5420333A (member.php)
EP (2) EP0597107B1 (member.php)
JP (1) JP2839805B2 (member.php)
KR (1) KR100252428B1 (member.php)
AT (2) ATE175954T1 (member.php)
DE (2) DE69228262D1 (member.php)
DK (2) DK0597107T3 (member.php)
ES (2) ES2091488T3 (member.php)
GR (1) GR3020461T3 (member.php)
HU (1) HU211296A9 (member.php)
TW (1) TW209215B (member.php)
WO (1) WO1993008155A1 (member.php)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0646570B1 (en) * 1993-04-16 1998-06-24 Shionogi & Co., Ltd. Process for producing lignan compound
FR2707980B1 (fr) * 1993-07-20 1995-09-01 Adir Nouveaux cyclohept[b]indoles et cyclooct[b]indoles, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JP3655311B2 (ja) * 1994-06-22 2005-06-02 塩野義製薬株式会社 フタリド化合物の製造方法
ID18046A (id) * 1996-08-20 1998-02-19 Takeda Chemical Industries Ltd Senyawa siklik campuran, pembuatan dan penngunaannya.
KR20010080428A (ko) * 1998-11-12 2001-08-22 케네쓰 아이. 모크 글루코스 및 지질을 저하시키는 화합물
KR100352269B1 (ko) * 1999-10-08 2002-09-12 한국생명공학연구원 저밀도 지질 단백질에 대해 항산화 활성을 갖는 리그난계 화합물
FR2800738B1 (fr) 1999-11-04 2002-02-08 Corning Sa Naphtopyranes ayant un substituant perfluoroalkyle en position 5, preparation et compositions et matrices (co)polymeres les renfermant
US6770024B1 (en) 2000-03-28 2004-08-03 Stony Brook Surgical Innovations, Inc. Implantable counterpulsation cardiac assist device
TWI241195B (en) * 2000-04-10 2005-10-11 Shionogi & Co Preventive agent for bile acidic diarrhea
WO2002009757A1 (en) * 2000-08-01 2002-02-07 Shionogi & Co., Ltd. Preventives or remedies for obesity or fatty liver
AU2003271115A1 (en) * 2002-10-08 2004-05-04 Shionogi And Co., Ltd. Process for producing enone ester
US7152611B2 (en) * 2002-12-30 2006-12-26 International Tape Partners, Llc Coated multifilament dental devices overcoated with imbedded particulate
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
EP2995317A1 (en) 2010-05-26 2016-03-16 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EP2771003B1 (en) 2011-10-28 2017-04-19 Lumena Pharmaceuticals LLC Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
KR102051031B1 (ko) 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
CA2907214A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
MX2015013193A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores del reciclaje de acidos biliares para el tratamiento de colangitis esclerosante primaria y enfermedad inflamatoria intestinal.
WO2020167981A1 (en) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Methods for increasing growth in pediatric subjects having cholestatic liver disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771072A (en) * 1985-01-10 1988-09-13 Tanabe Seiyaku Co., Ltd. Alkoxynaphthalene derivatives
JPS6310746A (ja) * 1986-07-01 1988-01-18 Tanabe Seiyaku Co Ltd ナフタレン誘導体
JPH0372422A (ja) * 1989-05-16 1991-03-27 Tanabe Seiyaku Co Ltd 抗脂血剤

Also Published As

Publication number Publication date
KR930703236A (ko) 1993-11-29
DK0597107T3 (da) 1996-07-29
JP2839805B2 (ja) 1998-12-16
DE69228262D1 (de) 1999-03-04
EP0597107B1 (en) 1996-07-03
DE69211994T2 (de) 1997-02-20
WO1993008155A1 (fr) 1993-04-29
US5420333A (en) 1995-05-30
ES2091488T3 (es) 1996-11-01
DE69211994D1 (de) 1996-08-08
ATE175954T1 (de) 1999-02-15
DK0701991T3 (da) 1999-09-13
ATE139990T1 (de) 1996-07-15
EP0597107A4 (en) 1994-02-03
US5731455A (en) 1998-03-24
US5502216A (en) 1996-03-26
US5449814A (en) 1995-09-12
JPH05310634A (ja) 1993-11-22
HU211296A9 (en) 1995-11-28
EP0701991A1 (en) 1996-03-20
ES2129733T3 (es) 1999-06-16
EP0701991B1 (en) 1999-01-20
GR3020461T3 (en) 1996-10-31
EP0597107A1 (en) 1994-05-18
KR100252428B1 (ko) 2000-04-15

Similar Documents

Publication Publication Date Title
TW209215B (member.php)
DE69232072T2 (de) Endothelin-rezeptor-antagonisten
DE3888821T2 (de) Tricyclische Verbindungen.
KR100660788B1 (ko) 벤조푸란 유도체, 그 제조법 및 용도
DE69827786T2 (de) Condensierte pyridazine derivate,deren herstellung und verwendung
IE59813B1 (en) Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them
JPH06506467A (ja) 多環式三級アミンポリ芳香族スクアレンシンセターゼインヒビター
JPS59101484A (ja) 新規なアリ−ルフエニルエ−テル誘導体及びその製造法
JPWO2005063222A1 (ja) Hsp90ファミリー蛋白質阻害剤
JPS6314703B2 (member.php)
JPS61267560A (ja) ピリダジノン誘導体
PT92945B (pt) Processo para a preparacao de derivados de acido benzociclo-alcenil-dihidroxi-alcanoico e de composicoes farmaceuticas que os contem
DD209446A5 (de) Verfahren zur herstellung von neuen aromatischen verbindungen
IE44362B1 (en) Dibenzocycloheptenylidene piperidines
AT414125B (de) Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln
Girotra et al. Development, synthesis, and biological evaluation of (-)-trans-(2S, 5S)-2-[3-[(2-oxopropyl) sulfonyl]-4-n-propoxy-5-(3-hydroxypropoxy)-phenyl]-5-(3, 4, 5-trimethoxyphenyl) tetrahydrofuran, a potent orally active platelet-activating factor (PAF) antagonist and its water-soluble prodrug phosphate ester
US4444774A (en) 7-Heteroaryl[1,2,4]triazolo[1,5-a]pyrimidines
EP1847535A1 (en) 1-(piperidin-4-yl)-1h-indole derivative
IE55991B1 (en) Bicyclic benzo fused compounds
JPH0130821B2 (member.php)
WO1993015080A1 (en) Azabicyclo compounds as calcium channel antagonists
NZ238055A (en) 4-amino-7-oxo-tetrahydrobenzothienopyridine-3-carboxylic acid derivatives, precursors and medicaments
DE2755727A1 (de) Derivate des 1,2,4-triazolidin- 2,5-dions, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JP2961534B1 (ja) 縮合ピリダジン誘導体、その製造法および用途
EP0924204A1 (en) 2-phenylmorpholin-5-one derivatives and pharmaceutical composition comprising the same